$ cat ./records/gates-foundation-commits-1-4-billion-to-fp2030-partnership-2020.txt
Gates Foundation Commits $1.4 Billion to FP2030 Partnership
[RECORD.TXT] · cat --full
The Gates Foundation pledged $1.4 billion over five years to FP2030, the successor framework to FP2020, at its global launch alongside commitments from UNFPA, IPPF, and bilateral donors totalling over $3.1 billion. The Gates contribution specifically targeted development of new contraceptive methods designed to be used independently by women without clinic visits, training of private-sector providers including pharmacies, and expanding supply chains to reach underserved communities. FP2030 operates in 120 countries with a renewed emphasis on adolescent and post-partum family planning.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Breakthrough Energy Ventures Co-Leads $100 Million Round for Pivot Bio Nitrogen Microbes
Next →
Gates Foundation Backs Broad Institute Sentinel Genomic Surveillance Network in West Africa
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.